@jennifer-carroll Thank you for your response. As a follow up question, in the context of an RWE publication, would the use of descriptive statistics to evaluate clinical outcomes preclude the use of the publication in a tool? Assuming that the analysis and endpoints were prespecified.
C
cchristopoulos
@cchristopoulos
Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
Posts
-
Use of descriptive statistics -
Use of descriptive statisticsCan trials that use descriptive statistics for their statistical methods be considered in a promotional setting (unbranded or branded)? If trials that use descriptive statistics can be used in APS, what are the considerations for use i.e. disclosures, limited to only one setting?
-
Pharmacogenetic trials and RWE@jennifer-carroll Thank you for your response! As a follow up question, can you clarify what defines"clinically relevant"?
-
Pharmacogenetic trials and RWEAssuming that a trial met the criteria of the RWE guidance, would a pharmacogenetic study evaluating a specific population be acceptable if the approved indication of the product was non-specific i.e. general population vs. select demographic? As a secondary point, given that it's a pharmacogenetic study and not an efficacy driven study, would there be any limitations to including data in APS if the results are only pharmacokinetic in nature?
-
Redirecting user via QR codeCan we change the eFile that links out of a QR code post approval (assuming no changes to layout or copy to the original APS)? For example, once an HCP branded Journal Ad with a QR code is approved for use, can we update the redirect from the QR code to another branded HCP eFile? If the QR code on the Journal Ad originally redirected to a digitally hosted APS (and was approved), but then once a mobile HCP branded website is launched, can we simply change the redirect? Or would we need to resubmit the Journal Ad as an update and indicate that the eFile has been changed for the QR code?